Lawsuits Filed Against NAK, NERV and OTGLY - Jakubowitz Law Pursues Shareholders Claims

NEW YORK, NY / ACCESSWIRE / January 25, 2021 /Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.

Northern Dynasty Minerals Ltd. (NYSE:NAK)

CONTACT JAKUBOWITZ ABOUT NAK:
https://claimyourloss.com/securities/northern-dynasty-minerals-ltd-loss-submission-form/?id=12396&from=1

Class Period : December 21, 2017 - November 25, 2020

Lead Plaintiff Deadline: February 2, 2021

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) the Company's Pebble Project was contrary to Clean Water Act guidelines and to the public interest; (2) the Company planned that the Pebble Project would be larger in duration and scope than conveyed to the public; (3) as a result, the Company's permit applications for the Pebble Project would be denied by the U.S. Army Corps of Engineers; and (4) as a result, Defendants' public statements were materially false and/or misleading at all relevant times.

Minerva Neurosciences, Inc. (NASDAQ:NERV)

CONTACT JAKUBOWITZ ABOUT NERV:
https://claimyourloss.com/securities/minerva-neurosciences-inc-loss-submission-form/?id=12396&from=1

Class Period : May 15, 2017 - November 30, 2020

Lead Plaintiff Deadline: February 8, 2021

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) the truth about the feedback received from the FDA concerning the “end-of-Phase 2” meeting; (ii) the Phase 2b study did not use the commercial formulation of roluperidone and was conducted solely outside of the United States; (iii) the failure of the Phase 3 study to meet its primary and key secondary endpoints rendered that study incapable of supporting substantial evidence of effectiveness; (iv) the Company's plan to use the combination of the Phase 2b and Phase 3 studies would be “highly unlikely” to support the submission of an NDA; (v) reliance on these two trials in the submission of an NDA would lead to “substantial review issues” because the trials were inadequate and not well-controlled; and (vi) as a result, the Company's public statements were materially false and misleading at all relevant times.

CD Projekt S.A. (OTCMKT:OTGLY)

CONTACT JAKUBOWITZ ABOUT OTGLY:
https://claimyourloss.com/securities/cd-projekt-s-a-loss-submission-form/?id=12396&from=1

Class Period : January 16, 2020 - December 17, 2020

Lead Plaintiff Deadline: February 22, 2021

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: Throughout the class period, defendants were materially false and/or misleading because they misrepresented and failed to disclose the following adverse facts pertaining to the Company's business, operations and prospects, which were known to Defendants or recklessly disregarded by them. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Cyberpunk 2077 was virtually unplayable on the current-generation Xbox or Playstation systems due to an enormous number of bugs; (2) as a result, Sony would remove Cyberpunk 2077 from the Playstation store, and Sony, Microsoft and the Company would be forced to offer full refunds for the game; (3) consequently, the Company would suffer reputational and pecuniary harm; and (4) as a result, Defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887

SOURCE:Jakubowitz Law

View source version on accesswire.com:
https://www.accesswire.com/625728/Lawsuits-Filed-Against-NAK-NERV-and-OTGLY--Jakubowitz-Law-Pursues-Shareholders-Claims

© 2021 Accesswire. All Rights Reserved.